A large proportion of patients with coronary artery disease treated with elective percutaneous coronary intervention have high residual platelet reactivity 1 and endothelial dysfunction, which might represent the link to the occurrence of ischemic events.
versus 11.6±3.9%, P<0.001; NMD, 18.7±5.2% versus 14.8±4.5%, P=0.007). On the other hand, ticagrelor resulted overall in significantly lower platelet reactivity (28±31 versus 116±58 P2Y 12 reaction units, P<0.001) and higher platelet inhibition (87±15% versus 51±22, P<0.001) in comparison with high-dose clopidogrel.
The interaction between platelets and endothelium is well established, and so is the potential benefit that antiplatelet drugs exert on the arterial wall, independent of platelet inhibition. 2 Clopidogrel, a thienopyridine irreversibly blocking ADP P2Y 12 receptor, is able to increase the endothelial cell production of nitric oxide, with an attendant dose-dependent improvement in endothelial function. Ticagrelor is an allosteric antagonist of ADP and, contrary to clopidogrel, reversibly blocks P2Y 12 receptor. Torngren et al 5 observed that, in patients with a previous acute coronary syndrome, those treated with ticagrelor had significantly better endothelial function than patients on clopidogrel or prasugrel. A possible mechanistic explanation for the improved vasoreactivity achieved with ticagrelor might relate to the increased adenosine availability obtained through the inhibition of adenosine cell uptake and the increased ATP release from human red blood cells. 6 Both mediators are in fact able to induce vasodilation: adenosine mediates relaxation of smooth muscular cells, whereas ATP promotes the release of nitric oxide, endothelial hyperpolarization factor, and prostacyclins from the endothelium. Moreover, it has been shown that ticagrelor is able to enhance vasodilation response to adenosine. Finally, another possible mechanism for these off-target effects of ticagrelor could relate to the expression of P2Y 12 receptors on vascular smooth muscle cells.
Despite limitations including relatively small sample size, short duration, no washout period between different study phases, and uncertain clinical correlation of changes in these arterial measures, the results of the CLOTILDIA study suggest for the first time that, in patients with type 2 diabetes mellitus and stable coronary artery disease treated with percutaneous coronary intervention, antiplatelet therapy with ticagrelor versus high-dose clopidogrel, in addition to aspirin, is able to provide, besides more profound platelet inhibition, a significant improvement in endothelial function and endothelium-independent brachial artery reactivity. Additional studies are warranted to explore the clinical impact of these findings and weigh the opportunity to extend the use of ticagrelor also to patients with stable coronary artery disease who are at high risk, such as those with diabetes mellitus.
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Figure. Study end points.
Flow-mediated dilation (FMD), nitroglycerin-mediated dilation (NMD), P2Y 12 reaction units (PRU), and platelet inhibition (PI) in the 2 treatment groups at the 3 time points. Values are reported as mean and standard deviation.
